This transcript captures a press conference led by Donald Trump announcing a major agreement with AstraZeneca, the UK's largest pharmaceutical manufacturer, to significantly lower prescription drug prices for Americans. The core of the deal is the implementation of a "Most Favored Nation" (MFN) pricing model, ensuring that Americans, particularly those on Medicaid, will pay the lowest price for AstraZeneca's drugs available anywhere in the world. Key components of the agreement include the launch of a new transparent pricing website, TrumpRX.gov, and a commitment from AstraZeneca to invest $50 billion in the United States for research, development, and onshoring of manufacturing facilities. The announcement features supporting remarks from members of Trump's administration and AstraZeneca's CEO, who frame the deal as a historic achievement made possible by the administration's use of tariffs as leverage. The press conference concludes with a Q&A session covering topics such as US-China relations, a Middle East peace deal, a potential government shutdown, and domestic crime.
White House Announces Major Drug Pricing Deal with AstraZeneca
00:35:29 Historic Announcement: Donald Trump announces a major agreement with the pharmaceutical company AstraZeneca aimed at significantly lowering prescription drug prices for Americans.
00:36:02 Most Favored Nation Pricing: AstraZeneca, the largest pharmaceutical manufacturer in the UK, has committed to a "Most Favored Nation" (MFN) pricing clause. This means Americans will pay the lowest price for their prescription drugs that is offered anywhere in the world.
00:38:03 MFN for Medicaid: A key part of the deal is AstraZeneca offering all of its prescription medications to Medicaid at MFN prices, which is projected to save American taxpayers hundreds of millions of dollars annually.
00:39:22 New Website and Price Reductions: Many of AstraZeneca's most popular drugs will be listed on a new website, TrumpRX.gov, at heavily discounted prices. Trump highlights potential price reductions of up to 654% on specific medications for COPD, asthma, and diabetes.
00:40:22 $50 Billion U.S. Investment: AstraZeneca commits to investing $50 billion in the United States over the next five years. This investment will fund research and development and the onshoring of manufacturing facilities, including a new plant in Charlottesville, Virginia, expected to create 3,600 jobs.
00:42:29 Contrasting with Previous Policies: Secretary Robert F. Kennedy Jr. argues this MFN deal is vastly superior to the previous administration's IRA drug price negotiations, which he claims were ineffective and often resulted in Medicare paying higher prices.
00:44:43 Tariffs Used as Leverage: Kennedy and Trump state that the administration's use of tariffs was the key leverage that successfully brought pharmaceutical giants like Pfizer and AstraZeneca to the negotiating table to accept these terms.
00:54:35 AstraZeneca CEO Confirms Commitment: CEO Pascal Soriot praises the deal as an "equalization" that rebalances the global cost of R&D, which he states has been disproportionately funded by American consumers for too long.
01:00:41 Major Impact on State Budgets: Virginia Governor Glenn Youngkin explains that the MFN pricing for Medicaid will result in massive savings for states, potentially hundreds of millions of dollars annually for Virginia, while also enhancing national security by bringing critical manufacturing back to the U.S.
01:09:07 Q&A: Middle East Peace Deal: During the Q&A, Trump discusses a new peace deal for Gaza, stating that hostages will be returned starting Monday and that he is confident the ceasefire will hold. He announces plans to speak at the Knesset in Israel and visit Egypt.
01:15:19 Q&A: Government Shutdown: When asked about a potential government shutdown, Trump states that resulting layoffs of federal workers will be "Democrat oriented."